Where is ERAS in the management of advanced ovarian cancer?: between myths and truths.
作者信息
Noh Joseph J, Lee Yoo-Young
机构信息
Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
出版信息
J Gynecol Oncol. 2022 Sep;33(5):e79. doi: 10.3802/jgo.2022.33.e79.
Abstract
摘要
相似文献
1
Where is ERAS in the management of advanced ovarian cancer?: between myths and truths.在晚期卵巢癌管理中，加速康复外科（ERAS）处于什么位置？：介于神话与真相之间。
J Gynecol Oncol. 2022 Sep;33(5):e79. doi: 10.3802/jgo.2022.33.e79.
2
A prospective study evaluating the impact of implementing the ERAS protocol on patients undergoing surgery for advanced ovarian cancer.一项前瞻性研究评估了实施 ERAS 协议对接受晚期卵巢癌手术的患者的影响。
Int J Gynecol Cancer. 2019 Mar;29(3):605-612. doi: 10.1136/ijgc-2018-000043. Epub 2019 Jan 4.
3
Evaluation of perioperative management of advanced ovarian (tubal/peritoneal) cancer patients: a survey from MITO-MaNGO Groups.评估高级卵巢（输卵管/腹膜）癌患者的围手术期管理：MITO-MaNGO 组的一项调查。
J Gynecol Oncol. 2022 Sep;33(5):e60. doi: 10.3802/jgo.2022.33.e60. Epub 2022 Jun 3.
4
Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol.实施术后加速康复（ERAS）方案后卵巢癌患者一线治疗期间静脉血栓栓塞的风险
Gynecol Oncol. 2021 Aug;162(2):353-359. doi: 10.1016/j.ygyno.2021.05.032. Epub 2021 Jun 3.
5
The impact of Enhanced Recovery after Surgery (ERAS) pathways with regard to perioperative outcome in patients with ovarian cancer.加速康复外科（ERAS）路径对卵巢癌患者围手术期结局的影响。
Arch Gynecol Obstet. 2022 Jul;306(1):199-207. doi: 10.1007/s00404-021-06339-6. Epub 2021 Dec 27.
6
PROFAST: A randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery.PROFAST：一项实施强化术后康复的随机试验，用于高复杂性晚期卵巢癌手术。
Eur J Cancer. 2020 Sep;136:149-158. doi: 10.1016/j.ejca.2020.06.011. Epub 2020 Jul 18.
7
The costs of adding laparoscopy to the management of advanced stage epithelial ovarian cancer.
Gynecol Oncol. 2017 Sep;146(3):441-442. doi: 10.1016/j.ygyno.2017.07.140.
8
Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: Old and Novel Questions.晚期卵巢癌的腹腔内化疗：旧问题与新问题
J Clin Oncol. 2019 Nov 20;37(33):3168-3169. doi: 10.1200/JCO.19.01163. Epub 2019 Sep 25.
9
Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer.晚期上皮性卵巢癌系统治疗相关影像学表现概述。
Abdom Radiol (NY). 2020 Mar;45(3):828-841. doi: 10.1007/s00261-019-02175-0.
10
Living Through Ovarian Cancer Treatment: Acute and Long-Term Toxicities of Chemotherapy for Advanced-Stage Disease.
Hematol Oncol Clin North Am. 2018 Dec;32(6):1073-1085. doi: 10.1016/j.hoc.2018.07.009.
引用本文的文献
1
Initial experience with the enhanced recovery after surgery (ERAS) protocols in gynecologic surgery at an urban academic tertiary medical center.在一家城市学术型三级医疗中心开展妇科手术术后加速康复（ERAS）方案的初步经验。
Gland Surg. 2024 Jan 29;13(1):19-31. doi: 10.21037/gs-23-249. Epub 2024 Jan 25.
本文引用的文献
1
Evaluation of perioperative management of advanced ovarian (tubal/peritoneal) cancer patients: a survey from MITO-MaNGO Groups.评估高级卵巢（输卵管/腹膜）癌患者的围手术期管理：MITO-MaNGO 组的一项调查。
J Gynecol Oncol. 2022 Sep;33(5):e60. doi: 10.3802/jgo.2022.33.e60. Epub 2022 Jun 3.
2
The implementation of enhanced recovery after surgery protocols in ovarian malignancy surgery.卵巢恶性肿瘤手术中术后加速康复方案的实施
Gland Surg. 2021 Mar;10(3):1182-1194. doi: 10.21037/gs.2020.04.07.
3
PROFAST: A randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery.PROFAST：一项实施强化术后康复的随机试验，用于高复杂性晚期卵巢癌手术。
Eur J Cancer. 2020 Sep;136:149-158. doi: 10.1016/j.ejca.2020.06.011. Epub 2020 Jul 18.
4
Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations-2019 update.妇科肿瘤围手术期护理指南：加速康复外科（ERAS）协会推荐-2019 更新版。
Int J Gynecol Cancer. 2019 May;29(4):651-668. doi: 10.1136/ijgc-2019-000356. Epub 2019 Mar 15.
5
A prospective study evaluating the impact of implementing the ERAS protocol on patients undergoing surgery for advanced ovarian cancer.一项前瞻性研究评估了实施 ERAS 协议对接受晚期卵巢癌手术的患者的影响。
Int J Gynecol Cancer. 2019 Mar;29(3):605-612. doi: 10.1136/ijgc-2018-000043. Epub 2019 Jan 4.
6
Impact of interval from primary cytoreductive surgery to initiation of adjuvant chemotherapy in advanced epithelial ovarian cancer.原发性细胞减灭术后至辅助化疗开始时间对晚期上皮性卵巢癌的影响。
Int J Gynaecol Obstet. 2018 Dec;143(3):325-332. doi: 10.1002/ijgo.12653. Epub 2018 Sep 19.
7
Health-related quality of life in ovarian cancer patients and its impact on clinical management.卵巢癌患者的健康相关生活质量及其对临床管理的影响。
Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):421-31. doi: 10.1586/erp.11.41.
8
A clinical pathway for patients undergoing primary cytoreductive surgery with rectosigmoid colectomy for advanced ovarian and primary peritoneal cancers.针对晚期卵巢癌和原发性腹膜癌患者行乙状结肠直肠切除术的初次肿瘤细胞减灭术的临床路径。
Gynecol Oncol. 2008 Feb;108(2):282-6. doi: 10.1016/j.ygyno.2007.10.014. Epub 2007 Nov 19.
9
Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.完全细胞减灭术在晚期上皮性卵巢癌患者中是可行的且能使生存率最大化：一项前瞻性研究。
Gynecol Oncol. 1998 May;69(2):103-8. doi: 10.1006/gyno.1998.4955.
Zotero 插件